We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 15, 2020

PD-L1 Expression Associated With Response to Neoadjuvant Durvalumab in TNBC

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
PD-L1 Protein Expression on Both Tumor Cells and Macrophages Are Associated With Response to Neoadjuvant Durvalumab With Chemotherapy in Triple-Negative Breast Cancer
Clin. Cancer Res 2020 Jul 24;[EPub Ahead of Print], FS Ahmed, P Gaule, J McGuire, K Patel, K Blenman, L Pusztai, DL Rimm

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading